目的 觀察抗婦炎膠囊聯(lián)合重組人干擾素α2a治療慢性宮頸炎的臨床療效。方法 選取2015年7月—2016年6月在武漢商職醫(yī)院就診的106例患者為研究對象，隨機分為對照組和治療組，每組各53例。對照組患者睡前陰道深部放置重組人干擾素α2a栓，1粒/次，隔日1次；治療組在對照組的基礎上口服抗婦炎膠囊，3粒/次，3次/d。兩組均連續(xù)治療30 d。治療后，觀察兩組患者臨床療效，同時比較治療前后兩組患者宮頸修復時間、臨床癥狀緩解時間以及不良反應情況。結果 治療后，對照組和治療組的總有效率分別為69.81%、88.68%，兩組比較差異具有統(tǒng)計學意義（P< 0.05）。治療后，治療組患者宮頸修復和臨床癥狀緩解時間均顯著短于對照組，兩組比較差異具有統(tǒng)計學意義（P< 0.05）。兩組均無明顯不良反應發(fā)生。結論 抗婦炎膠囊聯(lián)合重組人干擾素α2a臨床療效確切，組織修復快，不良反應較輕，具有一定的臨床推廣應用價值。

Objective To observe the clinical curative effect of Kangfuyan Capsules combined with recombinant human interferon α2a in treatment of chronic cervicitis. Methods Patients (106 cases) with chronic cervicitis in Wuhan Commercial Workers Hospital from July 2015 to June 2016 were randomly divided into control group and treatment group, and each group had 53 cases. Patients in the control group were were given Recombinant Human Interferon α2a Vaginal Suppositories at bedtime, 1 suppository/time, once every other day. Patients in the treatment group were po administered with Kangfuyan Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for three months. After treatment, the clinical efficacy was evaluated, and cervical repair time, remission time of clinical symptoms, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 69.81% and 88.68%, respectively, and there was difference between two groups (P < 0.05). After treatment, cervical repair time and remission time of clinical symptoms in the treatment group were shorter than those in the control group, and there was difference between two groups (P < 0.05). There were no adverse reactions in two groups.Conclusion Kangfuyan Capsules combined with recombinant human interferon α2a has clinical curative effect in treatment of chronic cervicitis with rapid tissue repair and less adverse reactions, which has a certain clinical application value.of clinical application.